ScholarIQanswers from OpenAlex

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors

PaperCitations, authors & open-access status

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors have?

ScholarIQcitation count

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors has 120 citations in the OpenAlex counts ScholarIQ stores.

When was Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors published?

ScholarIQyear

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors has 2021 year in the ScholarIQ index.

What is the open-access status of Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors?

ScholarIQoa status

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors has closed oa status in the ScholarIQ index.

What is the DOI of Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors?

ScholarIQdoi

The DOI for Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors is on the source record.

What is the PMID of Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors?

ScholarIQpmid

The PMID for Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors is on the source record.

What is the OpenAlex record for Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors?

ScholarIQopenalex

The OpenAlex for Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial